GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang East-Asia Pharmaceutical Co Ltd (SHSE:605177) » Definitions » 3-Year Revenue Growth Rate

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) 3-Year Revenue Growth Rate : 2.50% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zhejiang East-Asia Pharmaceutical Co 3-Year Revenue Growth Rate?

Zhejiang East-Asia Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥2.35.

During the past 12 months, Zhejiang East-Asia Pharmaceutical Co's average Revenue per Share Growth Rate was -10.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Zhejiang East-Asia Pharmaceutical Co was 8.40% per year. The lowest was -14.60% per year. And the median was 2.50% per year.


Competitive Comparison of Zhejiang East-Asia Pharmaceutical Co's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang East-Asia Pharmaceutical Co's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's 3-Year Revenue Growth Rate falls into.



Zhejiang East-Asia Pharmaceutical Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Zhejiang East-Asia Pharmaceutical Co  (SHSE:605177) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Zhejiang East-Asia Pharmaceutical Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Zhejiang East-Asia Pharmaceutical Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Business Description

Traded in Other Exchanges
N/A
Address
Laodong North Road, 23rd Floor, General Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Headlines

No Headlines